Literature DB >> 6146809

Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma.

D A Enria, A M Briggiler, N J Fernandez, S C Levis, J I Maiztegui.   

Abstract

P6 a retrospective study outcome in patients with Argentine haemorrhagic fever was associated with the amount of neutralising antibodies against Junin virus present in the transfused units of immune plasma. Low doses of neutralising antibodies were associated with higher mortality. A prospective study gave comparable results. A dose of no less than 3000 therapeutic units of neutralising antibodies per kg body weight is recommended. It is also suggested that the lack of effectiveness of immune plasma in the treatment of other viral haemorrhagic fevers, such as Lassa fever and Crimean-Congo haemorrhagic fever, may be due to a low dose of the specific neutralising antibodies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146809     DOI: 10.1016/s0140-6736(84)90299-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  59 in total

1.  Future opportunities for passive immunity against viral diseases.

Authors:  Barney S Graham
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

Review 2.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

3.  Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

Authors:  H Wang; M N Griffiths; D R Burton; P Ghazal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion.

Authors:  Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Genetic diversity among Bolivian arenaviruses.

Authors:  Maria N B Cajimat; Mary Louise Milazzo; Pierre E Rollin; Stuart T Nichol; Michael D Bowen; Thomas G Ksiazek; Charles F Fulhorst
Journal:  Virus Res       Date:  2008-12-19       Impact factor: 3.303

6.  Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain.

Authors:  Christian D Cuevas; Susan R Ross
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

7.  Current status of the treatment of Argentine Hemorrhagic Fever.

Authors:  D Enría; S G Franco; A Ambrosio; D Vallejos; S Levis; J Maiztegui
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

Review 8.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

9.  Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses.

Authors:  Selma Mahmutovic; Lars Clark; Silvana C Levis; Ana M Briggiler; Delia A Enria; Stephen C Harrison; Jonathan Abraham
Journal:  Cell Host Microbe       Date:  2015-12-09       Impact factor: 21.023

Review 10.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.